This December, the oncology community will travel across the US and beyond to discuss the latest developments in cancer care at three key medical conferences: the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH) in San Diego, California; the annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas; and the 17th IASLC World Conference On Lung Cancer (WCLC) in Vienna, Austria.
We at Novartis are excited to join the community and present data in leukemia, lymphoma, myeloproliferative neoplasms (MPNs), chronic iron overload, ALK+ advanced non-small cell lung cancer and advanced breast cancer. With these presentations, we hope to demonstrate our focus on advancing the science of cancer treatment, whether that is by pioneering the first personalized cell therapies and next-generation immuno-oncology, finding ways to delay progression in advanced lung and breast cancers or exploring the next step in our commitment to advancing care for some patients with chronic myeloid leukemia.
Many of these presentations are the result of years of work and collaboration by scientists, chemists, disease area specialists, clinicians, patients and more. We are united in our passion for improving patient care and finding new therapies for cancer, and that is what motivates us day in and day out.
Join the conversation on Twitter by following @NovartisCancer and using #ASH16, #SABCS16 and #WCLC2016. We will also be sharing stories on NovartisOncology.com that give an inside look into the science, a patient’s experience, a team of researchers’ work on a particular treatment and more.